Über Website:

Domänenname - tildrakizumab.de

Seitentitel - Seitentitel nicht verfügbar

Gehe zur Website - Link blockiert

Site Logo

%
% Terms and Conditions of Use
%
% The above data may only be used within the scope of technical or
% administrative necessities of Internet operation or to remedy legal
% problems.
% The use for other purposes, in particular for advertising, is not permitted.
%
% The DENIC whois service on port 43 doesn't disclose any information concerning
% the domain holder, general request and abuse contact.
% This information can be obtained through use of our web-based whois service
% available at the DENIC website:
% http://www.denic.de/en/domains/whois-service/web-whois.html
%
%

Domain: tildrakizumab.de
Status: redemptionPeriod
Changed: 2024-05-31T07:26:51+02:00

Brief facts about tildrakizumab:

Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union. Tildrakizumab was designed to block interleukin-23, a cytokine that plays a key role in managing the immune system and autoimmune disease.

Monoclonal antibodies